Published in J Biol Chem on September 13, 2010
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem (2011) 1.40
Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget (2014) 1.28
A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis. Nat Med (2012) 1.20
The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration. PLoS One (2012) 1.18
Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. Cancers (Basel) (2014) 1.10
Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res (2012) 1.08
Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res (2011) 1.06
MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell Signal (2011) 1.01
Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas. Genes Dis (2015) 0.99
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res (2012) 0.98
Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities. Molecules (2012) 0.95
Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias. Cancers (Basel) (2014) 0.92
In vitro effects of a small-molecule antagonist of the Tcf/ß-catenin complex on endometrial and endometriotic cells of patients with endometriosis. PLoS One (2013) 0.88
MiR-376c down-regulation accelerates EGF-dependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line. PLoS One (2013) 0.87
Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression. Int J Biol Sci (2016) 0.85
Proteolysis during tumor cell extravasation in vitro: metalloproteinase involvement across tumor cell types. PLoS One (2013) 0.85
Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. Biochem J (2015) 0.84
The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7. BMC Cancer (2011) 0.84
A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells. J Biol Chem (2012) 0.83
A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells. J Biol Chem (2014) 0.82
Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. Clin Exp Metastasis (2013) 0.82
CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2. Br J Cancer (2014) 0.81
Recruitment of Matrix Metalloproteinase-9 (MMP-9) to the Fibroblast Cell Surface by Lysyl Hydroxylase 3 (LH3) Triggers Transforming Growth Factor-β (TGF-β) Activation and Fibroblast Differentiation. J Biol Chem (2015) 0.81
Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2). J Biol Chem (2013) 0.79
Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J Clin Invest (2016) 0.78
A Disintegrin and Metalloproteinase with Thrombospondin Motifs-5 (ADAMTS-5) Forms Catalytically Active Oligomers. J Biol Chem (2015) 0.77
Role of Nonmuscle Myosin II in Migration of Wharton's Jelly-Derived Mesenchymal Stem Cells. Stem Cells Dev (2015) 0.77
Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed) (2015) 0.76
Targeting the Wnt/β-catenin pathway in endometriosis: a potentially effective approach for treatment and prevention. Mol Cell Ther (2014) 0.75
The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands. ChemMedChem (2016) 0.75
Matrix metalloproteinase-9 expression is enhanced in renal parietal epithelial cells of zucker diabetic Fatty rats and is induced by albumin in in vitro primary parietal cell culture. PLoS One (2015) 0.75
Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization. ACS Med Chem Lett (2017) 0.75
CO-releasing molecules CORM2 attenuates angiotensin II-induced human aortic smooth muscle cell migration through inhibition of ROS/IL-6 generation and matrix metalloproteinases-9 expression. Redox Biol (2017) 0.75
Failure of matrix metalloproteinase-9 dimer induction by phorbol 12-myristate 13-acetate in normal human cell lines. Oncol Lett (2015) 0.75
Decreased Homodimerization and Increased TIMP-1 Complexation of Uteroplacental and Uterine Arterial Matrix Metalloproteinase-9 during Hypertension-in-Pregnancy. Biochem Pharmacol (2017) 0.75
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem (2017) 0.75
Establishment of oral squamous cell carcinoma cell line and magnetic bead-based isolation and characterization of its CD90/CD44 subpopulations. Oncotarget (2017) 0.75
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
Matrix metalloproteinases. J Biol Chem (1999) 12.08
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol (1994) 4.09
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta (2005) 3.06
Matrix metalloproteinases: structures, evolution, and diversification. FASEB J (1998) 2.74
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 2.71
Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem (1992) 2.34
Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood (2008) 1.98
Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A (2003) 1.91
M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res (1993) 1.66
Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol (2009) 1.65
The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein. J Neurosci (2008) 1.60
Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration. J Biol Chem (2004) 1.44
Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem (2000) 1.43
Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem (1995) 1.42
Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem (2008) 1.41
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev (2003) 1.38
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem (2006) 1.36
Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res (2001) 1.32
Inducible expression of tissue inhibitor of metalloproteinases-resistant matrix metalloproteinase-9 on the cell surface of neutrophils. Am J Respir Cell Mol Biol (2003) 1.29
Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res (1997) 1.25
Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci U S A (2002) 1.24
Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res (2004) 1.20
Fibroblast migration is mediated by CD44-dependent TGF beta activation. J Cell Sci (2008) 1.18
The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J (2004) 1.18
Structural basis of the adaptive molecular recognition by MMP9. J Mol Biol (2002) 1.18
Role of leukemia cell invadosome in extramedullary infiltration. Blood (2009) 1.16
High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. J Biol Chem (1998) 1.15
The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. J Biol Chem (1998) 1.13
Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem (1996) 1.06
Substrate recognition by gelatinase A: the C-terminal domain facilitates surface diffusion. Biophys J (2001) 1.01
Latent MMP-9 is bound to TIMP-1 before secretion. Biol Chem (2007) 1.01
Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J Biol Chem (2004) 1.01
Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10. Biochem J (2006) 1.00
The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int J Cancer (2009) 0.99
Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function. J Cell Physiol (2007) 0.97
Biochemistry. Mimicking posttranslational modifications of proteins. Science (2004) 0.96
MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol (2007) 0.92
Enrichment of collagen and gelatin degrading activities in the plasma membranes of human cancer cells. Cancer Res (1987) 0.86
Purification of matrix metalloproteinases by column chromatography. Nat Protoc (2008) 0.82
The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab (2008) 2.84
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev (2011) 2.48
Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost (2005) 2.07
Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia (2007) 1.97
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med (2013) 1.71
A thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect Immun (2009) 1.69
EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis (2002) 1.64
Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res (2004) 1.61
Rv1106c from Mycobacterium tuberculosis is a 3beta-hydroxysteroid dehydrogenase. Biochemistry (2007) 1.52
Wolbachia utilizes host microtubules and Dynein for anterior localization in the Drosophila oocyte. PLoS Pathog (2005) 1.49
Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities. PLoS Comput Biol (2009) 1.48
Cholesterol metabolism increases the metabolic pool of propionate in Mycobacterium tuberculosis. Biochemistry (2009) 1.45
Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration. J Biol Chem (2004) 1.44
A potential probe set of fluorescence in situ hybridization for detection of lung cancer in bronchial brushing specimens. J Cancer Res Clin Oncol (2012) 1.43
Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem (2008) 1.41
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem (2011) 1.40
Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol (2003) 1.39
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev (2003) 1.38
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. J Pharmacol Exp Ther (2002) 1.32
Mechanism of 4-chlorobenzoate:coenzyme a ligase catalysis. Biochemistry (2008) 1.31
Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett (2009) 1.30
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol (2004) 1.29
Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice. Gastroenterology (2011) 1.28
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A (2011) 1.28
Divergence of function in the hot dog fold enzyme superfamily: the bacterial thioesterase YciA. Biochemistry (2008) 1.28
Amino acid-bearing ROMP polymers with a stereoregular backbone. J Am Chem Soc (2006) 1.26
Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. Cancers (Basel) (2011) 1.26
The concentration of Nuf, a Rab11 effector, at the microtubule-organizing center is cell cycle regulated, dynein-dependent, and coincides with furrow formation. Mol Biol Cell (2007) 1.23
Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase a activation. Lab Invest (2002) 1.21
Vesicles and actin are targeted to the cleavage furrow via furrow microtubules and the central spindle. J Cell Biol (2008) 1.19
Romping the cellular landscape: linear scaffolds for molecular recognition. Curr Opin Struct Biol (2006) 1.18
Multivalent fertilinbeta oligopeptides: the dependence of fertilization inhibition on length and density. Chem Biol (2006) 1.18
Dynamic requirements for a functional protein hinge. J Mol Biol (2007) 1.16
The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res (2006) 1.15
Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res (2009) 1.15
The binding and release of oxygen and hydrogen peroxide are directed by a hydrophobic tunnel in cholesterol oxidase. Biochemistry (2008) 1.13
Pathway profiling in Mycobacterium tuberculosis: elucidation of cholesterol-derived catabolite and enzymes that catalyze its metabolism. J Biol Chem (2011) 1.13
Synthesis of copolymers by alternating ROMP (AROMP). J Am Chem Soc (2009) 1.13
Heme oxygenase: the key to renal function regulation. Am J Physiol Renal Physiol (2009) 1.12
Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem (2013) 1.12
Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer Res (2005) 1.10
Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer Biol Ther (2009) 1.10
Cholesterol oxidase senses subtle changes in lipid bilayer structure. Biochemistry (2004) 1.08
Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis (2008) 1.08
Angiogenesis is induced by airway smooth muscle strain. Am J Physiol Lung Cell Mol Physiol (2007) 1.08
Entropy effects on protein hinges: the reaction catalyzed by triosephosphate isomerase. Biochemistry (2004) 1.07
Cholesterol is not an essential source of nutrition for Mycobacterium tuberculosis during infection. J Bacteriol (2011) 1.07
Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res (2011) 1.06
Mechanical stretch induces MMP-2 release and activation in lung endothelium: role of EMMPRIN. Am J Physiol Lung Cell Mol Physiol (2002) 1.04
Comparison of fertilinbeta-peptide-substituted polymers and liposomes as inhibitors of in vitro fertilization. Chembiochem (2003) 1.03
CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett (2004) 1.03
CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res (2004) 1.03
Cholesterol oxidase: physiological functions. FEBS J (2009) 1.02
Cyclic mechanical strain-induced proliferation and migration of human airway smooth muscle cells: role of EMMPRIN and MMPs. FASEB J (2005) 1.02
Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. J Am Soc Nephrol (2013) 1.01
Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration. J Natl Cancer Inst (2013) 1.01
Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer. PLoS One (2012) 1.00
A facile synthetic method to prepare fluorescently labeled ROMP polymers. Org Lett (2004) 1.00
Increased polymer length of oligopeptide-substituted polynorbornenes with LiCl. J Org Chem (2003) 1.00
Intracellular processing and activation of membrane type 1 matrix metalloprotease depends on its partitioning into lipid domains. J Cell Sci (2004) 0.99
Antibacterial studies of cationic polymers with alternating, random, and uniform backbones. ACS Chem Biol (2011) 0.97
Beta1 integrin is an adhesion protein for sperm binding to eggs. ACS Chem Biol (2009) 0.97
Symmetric and asymmetric mitotic segregation patterns influence Wolbachia distribution in host somatic tissue. J Cell Sci (2009) 0.97
Wavefront aberration measurements and corrections through thick tissue using fluorescent microsphere reference beacons. Opt Express (2010) 0.95
Fluoroketone inhibition of Ca(2+)-independent phospholipase A2 through binding pocket association defined by hydrogen/deuterium exchange and molecular dynamics. J Am Chem Soc (2013) 0.95
Loss of intercellular adhesion activates a transition from low- to high-grade human squamous cell carcinoma. Int J Cancer (2006) 0.94
Necrosis induction in glioblastoma cells reveals a new "bioswitch" function for the MT1-MMP/G6PT signaling axis in proMMP-2 activation versus cell death decision. Neoplasia (2007) 0.94
Off-resonance TROSY (R1 rho - R1) for quantitation of fast exchange processes in large proteins. J Am Chem Soc (2003) 0.93
In Vivo Chemiluminescent Imaging Agents for Nitroreductase and Tissue Oxygenation. Anal Chem (2016) 0.92
Updating and curating metabolic pathways of TB. Tuberculosis (Edinb) (2013) 0.92
Scope of the ring-opening metathesis polymerization (ROMP) reaction of 1-substituted cyclobutenes. J Am Chem Soc (2010) 0.92
Improved myocardial perfusion in chronic diabetic mice by the up-regulation of pLKB1 and AMPK signaling. J Cell Biochem (2010) 0.92
Improved arrhythmia detection in implantable loop recorders. J Cardiovasc Electrophysiol (2008) 0.92
MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival. J Biol Chem (2007) 0.91
Chemical genetics reveals an RGS/G-protein role in the action of a compound. PLoS Genet (2006) 0.91
Pathogen roid rage: cholesterol utilization by Mycobacterium tuberculosis. Crit Rev Biochem Mol Biol (2014) 0.91
Rational redesign of the 4-chlorobenzoate binding site of 4-chlorobenzoate: coenzyme a ligase for expanded substrate range. Biochemistry (2007) 0.91
Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis Markers (2012) 0.91
Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys (2003) 0.91
MiR-490-3p modulates the proliferation of vascular smooth muscle cells induced by ox-LDL through targeting PAPP-A. Cardiovasc Res (2013) 0.91
Cyclic alternating ring-opening metathesis polymerization (CAROMP). Rapid access to functionalized cyclic polymers. Org Lett (2010) 0.90
Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls. Clin Cancer Res (2005) 0.90